I still think that the use of easily manufacturable copper isotopes is what separates the company apart.
However, logistics and staff personnel is still required. Since CU6, does not have in house capabilities then it’ll be hard for big pharma to take that risk bc they will have to set up a whole division for this program
Research/Valuation, page-30
-
- There are more pages in this discussion • 510 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.30 |
Change
-0.160(2.48%) |
Mkt cap ! $1.963B | |||
| Open | High | Low | Value | Volume |
| $6.30 | $6.37 | $6.21 | $8.318M | 1.326M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $6.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.30 | 4052 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |